title: Generation of stimulated, lymphokine activated T killer (T-LAK) cells from the peripheral blood of normal donors and adult patients with recurrent glioblastoma.
abstract: Peripheral blood mononuclear cells (PBM) from normal donors and patients with recurrent glioma were activated initially for 48-72 h with phytohemagglutinin-P (PHA) and recombinant human interleukin-2 (IL-2), and then proliferated in vitro for up to 5 months with IL-2. These cells are termed mitogen-stimulated lymphokine-activated T killer (T-LAK) cells. We measured patterns of T-LAK cell growth, in vitro cytolytic activity on a panel of continuous and primary tumor cells, and the phenotypes of the cells in these cultures. Lymphocyte viability declined dramatically over the first 3-5 days; and then the remaining cells in these cultures began to divide and maintained a constant 30-36 h doubling time for long periods in vitro. Phenotyping revealed that cells in the initial few days of culture were heterogeneous, but became almost totally CD3 T cells after 7-10 days in culture. The T-LAK cells from individual normal donors and cancer patients demonstrated a non-genetically restricted cytolytic ability against a panel of both continuous cell lines and primary autologous and allogeneic glioblastoma cells in vitro. This technique provides a method of generating large numbers of autologous cytolytic T cells with non-restricted anti-tumor activity that can be derived from peripheral blood mononuclear cells.
authors.affiliation: Health Care Medical Center of Tustin, CA 92681.
authors.forename: R S
authors.initials: RS
authors.lastname: Yamamoto
authors.forename: J
authors.initials: J
authors.lastname: Coss
authors.forename: B
authors.initials: B
authors.lastname: Vayuvegula
authors.forename: S
authors.initials: S
authors.lastname: Gupta
authors.forename: Y
authors.initials: Y
authors.lastname: Beamer
authors.forename: S
authors.initials: S
authors.lastname: Jacques
authors.forename: E W
authors.initials: EW
authors.lastname: Jeffes
authors.forename: W E
authors.initials: WE
authors.lastname: Carson
authors.forename: J
authors.initials: J
authors.lastname: Jakowatz
authors.forename: G A
authors.initials: GA
authors.lastname: Granger
mesh_terms: D000328:Adult; D000943:Antigens, Differentiation / Q000276:immunology; D000954:Antigens, Surface / Q000276:immunology; D001932:Brain Neoplasms / Q000097:blood* / Q000276:immunology; D002470:Cell Survival; D003602:Cytotoxicity, Immunologic / Q000276:immunology; D005910:Glioma / Q000097:blood* / Q000276:immunology; D006801:Humans; D016130:Immunophenotyping; D007376:Interleukin-2 / Q000494:pharmacology; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology*; D007963:Leukocytes, Mononuclear / Q000276:immunology; D008213:Lymphocyte Activation / Q000276:immunology*; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D010835:Phytohemagglutinins / Q000494:pharmacology; D011994:Recombinant Proteins / Q000494:pharmacology; D016176:T-Lymphocyte Subsets / Q000276:immunology*; D014407:Tumor Cells, Cultured
chemical_list: D000943:Antigens, Differentiation; D000954:Antigens, Surface; D007376:Interleukin-2; D010835:Phytohemagglutinins; D011994:Recombinant Proteins